



Key Figures – Eurofins Scientific Group

according to International Financial Reporting Standards (IFRS)


Sales in € Million




EBITDA in € Million



Average Number of Employees *



Number of countries



CAGR: Compound Annual Growth Rate

* FTE = Full Time Employees

Company Profile

A global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With about 8,000 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and expert advice by our highly qualified staff.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy to expand both its technology portfolio and its geographic reach. Through R&D, licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

Shareholders' information in short

Listings

NYSE Euronext Paris (since IPO on 24.10.1997)

Frankfurter Wertpapierbörse/ XETRA Frankfurt (since SPO on 26.10.2000)

Segments/ Indexes

Paris: Next 150 & SBF 250, Next Biotech and Compartment B

Frankfurt: Prime Standard/ Technology All Share

Industry Group/ Prime Sector

Pharma & Healthcare/Healthcare Providers

Codes

ISIN: FR 0000038259

Frankfurt: WKN 910251

Tickers

Paris: Reuters EUFI.LN, Bloomberg ERF FP

Frankfurt: ESF, EUFI.DE

Nominal Capital (as of 31.03.2009)

1,416,677.40 € (14,166,774 x 0.10 €)

Simplified Ownership Structure (31.03.2009)

47% Analytical Bioventures SCA

53% free float

Investor Relations

Eurofins Scientific Group

Phone: +32 2 769 7383

E-mail: ir@eurofins.com

Internet

www.eurofins.com

Disclaimer

THIS REPORT MAY CONTAIN FORWARD-LOOKING STATEMENTS AND ESTIMATES THAT INVOLVE RISKS AND UNCERTAINTIES. THE FORWARD-LOOKING STATEMENTS AND ESTIMATES CONTAINED HEREIN REPRESENT THE JUDGEMENT OF EUROFINS SCIENTIFIC AS OF THE DATE OF THIS RELEASE. THESE FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES FOR FUTURE PERFORMANCE, AND THE FORWARD-LOOKING

EVENTS DISCUSSED IN THIS REPORT MAY NOT OCCUR. EUROFINS SCIENTIFIC DISCLAIMS ANY INTENT OR OBLIGATION TO UPDATE ANY OF THESE FORWARD-LOOKING STATEMENTS AND ESTIMATES. ALL STATEMENTS AND ESTIMATES ARE MADE BASED ON THE DATA AVAILABLE TO THE COMPANY AS OF THE DATE OF PUBLICATION, BUT NO GUARANTEE CAN BE MADE AS TO THEIR VALIDITY.

Operating and Financial Review and Prospects

Financial figures in this report were prepared based on the International Financial Reporting Standards (IFRS). All accounts are consolidated at the Eurofins Scientific Group level. The Company's auditors have conducted a limited review on these accounts.

Dear Shareholders,

The first quarter has shown that in otherwise uncertain and volatile times, Eurofins is proving to be more than resilient, showing continued underlying growth. In spite of adverse currency effects and discontinued activities revenues have increased to €148.2m (Q1 2009) from €139.6m (Q1 2008), EBITDA has remained constant at €10.7m and EBITAS* is in line with overall expectations at €1.6m for Q1 2009 compared to €2.5m for Q1 2008.

The Q1 results are always the weakest of the four quarters. This was accentuated in 2009 by the impact of unusually severe weather in Europe on the Environmental business, making the testing of frozen or snow-covered soil and water almost impossible. There was also a degree of postponement of projects in the Pharma division. As organic growth was still over 5% it is too early to make judgements on any underlying short-term trends in Eurofins' markets. For the moment there is no reason to change expectations and certainly the number of food and health issues and new regulations around the world continues to grow.

A major area for focus in 2009 will be to continue the bringing up to Group standards of the Under Development perimeter. In its new scope (21% of Group revenues in Q1 2009) it reported a loss of -€5.8m in the first quarter, an improvement from -€6.2m for Q1 2008. Even at the current run-rate that would represent good progress from 2008 and the turn-around projects are going ahead as planned and on schedule. At the same time the Up to Standards perimeter reported good growth, at 8.8%, but as usual profitability in the quarter represents only a small proportion of expected full-year results.

In the cash flow statement Capital expenditure (€10.9m Q1 2009, €10.7m Q1 2008) was in line with full year expectations as the Group completes its current investment programme. Planned capex for 2009 is significantly below 2008 levels as a percentage of revenues (8.7% in 2008), so the Group should derive significant cash flow benefits over the course of the year. On the Balance Sheet the financing position is still comfortable, with the cash balance at €104.2m and covenants with lots of head room: Net Debt/EBITDA 2.2x and Net Debt/Equity 0.8x. Net debt at 31 March was €171.8m compared to €158.1m at 31 Dec 2008.

In summary, the first quarter is too minor to be considered meaningful. The feedback from the markets suggests that organic growth will continue to be positive in 2009 and the progress in margins will be driven by the improvements in the Under Development perimeter and that is going according to plan. The Eurofins Group considers itself well-oriented, internally and externally, to make excellent progress in the long term.

Sincerely,



Dr. Gilles G. Martin
CEO

Operating Revenues

Operating Revenues for Q1 2009 were €148.2m, an increase from €139.6m for Q1 2008. This is an overall increase of 6.2%. There has been some impact on a country by country basis mostly through exchange fluctuations in the British Pound, Swedish Krona and US Dollar.

Breakdown of sales by region

€ million	Q1 2009	%	Q1 2008	%
Benelux	19.6	13.3	16.7	12.0
British Isles	8.4	5.7	10.3	7.4
France	28.9	19.5	26.1	18.7
Germany	31.9	21.5	32.7	23.5
North America	16.9	11.4	15.2	10.9
Scandinavia	30.3	20.4	30.4	21.8
Other	12.2	8.2	8.2	5.9
Total	148.2	100	139.6	100

Net Income

Group EBITDA in the first quarter of 2009 remained constant at €10.7m (€10.7m Q1 2008). Reported operating profit (EBITAS*) went from €2.5m in Q1 2008 to €1.6m for Q1 2009. Although personnel costs were slightly up as a percentage of revenues (52.5% Q1 2009 vs 50.7% Q1 2008) the actual cost reduced from the previous quarter as restructuring continues and some flexibility is introduced (€77.9m in Q1 2009 from €80.7m in Q4 2008).

Within its new scope, the Up to Standards perimeter represented 79% of Group revenues and EBITAS earnings of €7.3m. This included growth of 8.8% but a small decrease in margin to 6.2% from 8.1% in Q1 2009 (on a same-scope basis), mainly due to the weather effect on sales in the environment division and some pharma contract postponements. The focus in the Under Development perimeter was primarily on improving profitability and losses in the perimeter were -€5.8m (Q1 2008 -€6.2m). The result is that even with the current run-rate some good progress is being made.

Cash Flow and Liquidity

Net cash from operating activities during the quarter was €6.5m compared to €9.7m for Q1 2008. The major difference between the two periods was due to the movement in net working capital, which in turn was attributable to a reduction in Trade Accounts Payable after the year end. As noted below, net working capital balances have historically been quite seasonal.

Amounts paid for acquisitions decreased 20% to €5.9m in Q1 2009 compared to €7.4m in Q1 2008. The principal component of this was deferred payments for acquisitions completed in prior periods. In the wider acquisitions market Eurofins sees no reason to alter its prudent approach as multiples are expected to come down going forward. Capital expenditure during the quarter was €10.9m, up from €10.7m in Q1 2008 and in line with the full year expected figure of around €50m. It is the Group's intention to complete its current investment programme, as noted in the 2008 annual results, but as an overall percentage of revenues capex will reduce significantly from the exceptionally

high levels of the last two years (10% in 2007, 9% in 2008), which in turn will have the direct effect of increasing cash flow.

The Group repaid €21.5m of borrowings during the period and cash and cash equivalents at the 31/3/2009 were €104.2m (31/12/2008 €131.7m).

Balance Sheet

Total assets at the end of the period were €706.6m (31/12/2008 €734.0m) and net debt was €171.8m (31/12/2008 €158.1m). The relevant covenants therefore were 0.8x Net Debt/Equity and 2.2x Net Debt/EBITDA, compared to 0.7x and 2.0x respectively at 31 December 2008. Net working capital increased to 6.7% of revenues from 4.8% at the year end and is entirely normal as can be seen from historic quarterly variations.

Sales and Marketing

The major development in this area during the first quarter was the announcement of an outsourcing deal with the DLG Group in Denmark, worth €10 million over five years. Eurofins will provide laboratory-based food and feed testing services as well as part of DLG's daily quality control process.

Eurofins won a number of contracts and tenders during the quarter, in each area of the business. The Food business signed an agreement to provide worldwide testing services for Barilla, worth over €2 million per year. In Environment testing the first public tender for drinking water was secured in France (Hauts de Seine), which is a useful start in the gradual deregulation of the French market. In Italy the Group also won contracts at the Policlinico Maggiore hospital and with Rennergies, one of Italy's biggest photovoltaic manufacturers.

Finally, also in the USA, Eurofins was accepted onto the initial phase of a large insecticide screening programme for a major client. Eurofins was selected to take part in this stage of the programme ahead of other CRO's which were more established in the USA.

Strategic Acquisitions and Geographic Expansion

As announced at the time of the Annual Results, Eurofins intends to carry out very few acquisitions in 2009 in order to focus on getting the best from its existing businesses. An additional benefit to the Group as a result of this is that during the year Eurofins expects the prices of potential acquisitions to reduce in line with market expectations.

Expansion did continue in a few small areas. In March the Agrosience business founded a new field station in Romania where it is to offer field trials. At the same time in the USA there was expansion to secure further field facilities in Champaign, Illinois and Jeffersonville, Georgia and a second site in Florida is being evaluated. Eurofins is now the world's leading provider of field trials and analytical testing to the Agrosiences industry.

R&D Initiatives and Infrastructure

The current investment in upgrading of Eurofins' laboratories and infrastructure continues as planned. A new capability for stability testing in Quality Control in the Pharma business has been completed in Paris which is of a particularly high standard when compared to the competition. Pharma in Italy have also invested in expanding laboratory and office space to 4,500 sq.m. and in various places throughout the Group capabilities are being expanded to cater for potential REACH business both upstream (substances) and downstream (articles).

Post Closing and Other Events

Since the end of the quarter, Eurofins has made progress at its laboratories in China. On 2nd April Dr Gilles Martin, CEO of the Eurofins Scientific Group, formally opened the food testing facility in Suzhou, just outside Shanghai. Soon after this date the same laboratory obtained its accreditation for ISO17025 by the German DACH, the first with such accreditation in China. Eurofins hopes that by providing testing that is the equal of anything available in Europe it will meet the requirements of the world's leading multinational food producers sourcing and exporting from the region.

At the annual shareholders meeting on the 13th May, the payment of a €0.10 dividend to ordinary shareholders was approved. In addition the Group will pay the coupon due to the Hybrid holders in May 2009.

Employees

The overall average weighted number of full time employees has increased to 7,020 in Q1 2009 (Q1 2008 6,432). Headcount was 7,652 (Q1 2008 7,369).

As of	31.03.2009	31.03.2008
Benelux	775	750
British Isles	479	595
France	1,376	1,227
Germany	1,667	1,612
North America	628	583
Scandinavia	1,265	1,199
Other	830	466
Total	7,020	6,432

Employee numbers are weighted average "Full time equivalents" (FTE) over the period, i.e. the figures are weighted by the time that (acquired) laboratories are fully consolidated in the Group.

The overall personnel costs for the Eurofins Scientific staff including social security and pension costs were €77.9m, representing 52.5% of revenues (€70.8m in Q1 2008, 50.7%)

Directors Holdings

The summary as of March 31, 2009 is listed below:

As of 31.03.2009	No. of Shares	No. of Stock Options
Gilles G. Martin	1	0
Valérie Hanote	1	0
Wicher R. Wichers	43,001	12,500
Yves-Loïc Martin	14,546	0

Analytical Bioventures SCA, which is controlled by Gilles and Yves-Loïc Martin, holds 6,659,570 shares.

*EBITAS – EBIT before non-cash accounting charge for stock options, impairment of goodwill and amortisation of intangible assets related to acquisitions

Consolidated Financial Statements

Consolidated Profit and Loss Statement

January 1, 2009 to March 31, 2009

€ Thousand	Q1/ 2009	Q1/ 2008
Revenues ¹	148,242	139,586
Cost of purchased materials and services	-59,448	-56,900
Personnel expenses	-77,899	-70,769
Other operating income and expenses, net ¹	-210	-1,210
EBITDA	10,685	10,707
Depreciation and amortisation	-9,135	-8,172
EBITAS ²	1,550	2,535
Non cash accounting charge for stock options (S.O.)	-548	-370
Impairment of goodwill and amortisation intangible assets related to acquisitions	-357	-215
EBIT after non cash accounting charge for S.O., impairment of goodwill and amortisation of intangible assets related to acquisitions	646	1,950
Finance income	639	263
Finance costs	-4,341	-3,888
Financial result	-3,702	-3,625
Share of (loss)/ profit of associates	27	15
Result before income taxes	-3,029	-1,660
Income tax expense	0	0
Net profit/ loss for the period	-3,029	-1,660
Net profit attributable to equity interest	-2,868	-1,948
Net profit attributable to minority interest	-161	288
Earnings per share (basic) in € - Total	-0.20	-0.14
Earnings per share (basic) in € - attributable to hybrid capital investors	0.14	0.14
Earnings per share (basic) in € - attributable to equity holders	-0.35	-0.28
Earnings per share (diluted) in € - Total	-0.19	-0.13
Earnings per share (diluted) in € - attributable to hybrid capital investors	0.13	0.13
Earnings per share (diluted) in € - attributable to equity holders	-0.32	-0.26
Weighted average shares outstanding (basic)	14,165	13,981
Weighted average shares outstanding (diluted)	15,298	15,140

¹ Reclassification for 2008 of analysis in progress for an amount of € 2,259K from the line "Other operating income and expenses, net" to the line "Revenues"

² EBITAS : EBIT before non cash accounting charge for S.O., impairment of goodwill and amortisation of intangible assets related to acquisitions

Consolidated Balance Sheet

As of March 31, 2009

€ Thousand	31.03.2009	31.12.2008
Property, plant and equipment	132,275	128,989
Goodwill	243,821	242,416
Other intangible assets	26,547	26,536
Investments in associates	2,204	2,157
Financial assets, trade and other receivables	5,258	5,219
Non-current assets held for sale	600	600
Deferred tax asset	16,917	16,111
Derivative financial instruments	0	0
Total non current assets	427,622	422,028
Inventories	6,829	7,649
Trade accounts receivable	142,599	149,691
Prepaid expenses and other current assets	21,514	17,463
Corporate tax receivable	3,908	5,513
Cash and cash equivalents	104,151	131,666
Total current assets	279,001	311,982
Total assets	706,623	734,010
Share capital	1,417	1,416
Other reserves	52,309	49,086
Hybrid capital	100,000	100,000
Retained earnings	55,467	62,084
Shareholders' equity – part of the Group	209,193	212,586
Minority interest	6,540	6,532
Total shareholders' equity	215,733	219,118
Borrowings	125,380	144,708
OBSAR Bonds	119,166	119,095
Derivative financial instruments	5,240	3,049
Deferred tax liability	5,958	7,776
Account payable on investment	31,130	31,388
Pension accrual	12,113	11,776
Provisions for other liabilities and charges	7,318	7,565
Total non current liabilities	306,305	325,357
Borrowings	31,454	25,933
Trade accounts payable	43,346	56,803
Advance payments received and deferred revenues	18,655	17,714
Corporate tax due	8,817	8,210
Account payable on investment	3,828	8,471
Other current liabilities	78,485	72,404
Total current liabilities	184,585	189,535
Total liabilities and shareholders' equity	706,623	734,010

Consolidated Cash Flow Statement

January 1, 2009 to March 31, 2009

€ Thousand	Q1/ 2009	Q1/ 2008
Cash flows from operating activities		
Result before income taxes	-3,029	-1,660
Adjustments for:		
Depreciation and amortisation	9,492	8,386
Increase/ decrease in provisions and accruals	96	-526
Losses/ gains on the disposal of fixed assets, investments in associates	-191	73
Non cash accounting charge for stock options	515	355
Financial income and expense, net	3,742	3,056
Expense/ income from investments (equity method)	-27	-15
Derivative financial instruments – income statement	0	0
Change in net working capital	-4,085	1,912
Cash generated from operations	6,513	11,582
Income taxes paid	-3	-1,876
Net cash provided by operating activities	6,510	9,706
Cash flows from investing activities		
Acquisitions of subsidiaries, net of cash acquired	-5,856	-7,382
Proceeds from sale of a subsidiary, net of cash transferred	0	0
Purchase of property, plant and equipment	-9,490	-10,242
Purchase of intangible assets	-1,403	-446
Proceeds from sale of property, plant and equipment	820	693
Purchase net of sales of investments and financial assets	-47	-125
Interest received	455	379
Net cash used in investing activities	-15,521	-17,123
Cash flows from financing activities		
Proceeds from issuance of share capital	55	148
Proceeds from short or long term borrowings	786	8,586
Cash repayments of amounts borrowed	-21,530	-3,237
OBSAR Bonds	71	0
Hybrid capital issue	0	0
Dividends to shareholders	0	0
Dividends to minority interest	0	0
Hybrid interest paid	0	0
Interest paid	-3,180	-2,500
Net cash provided by financing activities	-23,798	2,997
Net effect of currency translation in cash and cash equivalents	195	-339
Net increase (decrease) in liquid funds	-32,614	-4,759
Cash and cash equivalents and bank overdrafts at beginning of period	127,854	61,266
Cash and cash equivalents and bank overdrafts at end of period	95,240	56,506

Consolidated Statement of Changes in Equity

As of March 31, 2009

€ Thousand	Shareholders' equity part of the Group				Minority interest	Total Equity
	Share capital	Other reserves	Hybrid Capital	Retained earnings		
Balance at January 1, 2008	1,398	52,728	100,000	55,456	5,982	215,564
Currency translation differences	0	-3,394	0	-8	-26	-3,428
Financial instruments	0	0	0	-1,699	0	-1,699
Minority interest transfer	0	0		1	-1	0
Share based payments	0	0	0	355	0	355
Total income / expense recognised directly in equity	0	-3,394	0	-1,351	-27	-4,772
Net profit	0	0	0	-1,948	288	-1,660
Total income recognised in 2008	0	-3,394	0	-3,300	261	-6,433
Treasury stock	0	0	0	0	0	0
Deferred distribution on Hybrid Capital	0	0	0	-2,020	0	-2,020
Issue of share capital	1	147	0	0	0	148
Dividends	0	0	0	0	0	0
Potential payments in shares arising on business combinations	0	0	0	667	0	667
Minority interest arising on business combinations	0	0	0	0	-280	-280
Balance at March 31, 2008	1,399	49,481	100,000	50,803	5,963	207,646
Balance at January 1, 2009	1,416	49,086	100,000	62,084	6,532	219,118
Currency translation differences	0	3,168	0	8	26	3,202
Deferred taxes on net investments	0	0	0	-132	0	-132
Financial instruments	0	0	0	-2,191	0	-2,191
Minority interest transfer	0	0		71	-71	0
Non cash accounting charge for stock options	0	0	0	515	0	515
Total income / expense recognised directly in equity	0	3,168	0	-1,729	-45	1,394
Net profit	0	0	0	-2,868	-161	-3,029
Total income recognised in 2009	0	3,168	0	-4,597	-206	-1,635
Treasury stock	0	0	0	0	0	0
Deferred distribution on Hybrid Capital	0	0	0	-2,020	0	-2,020
Issue of share capital	1	55	0	0	0	56
Dividends	0	0	0	0	0	0
Minority interest arising on business combinations					214	214
Balance at March 31, 2009	1,417	52,309	100,000	55,467	6,540	215,733

Interim Notes

General

We inform you that these Interim Notes are summarised.

1. Accounting policies

Eurofins condensed interim financial statements for the 3 month period ending 31st March 2009 have been prepared according to IAS 34 – Interim financial reporting standard as adopted by the European Union.

As condensed interim financial statements, they do not include all information required by IFRS framework for the preparation of annual financial statements and have to be read in relation with the Group consolidated financial statements prepared for the year-end 2008 in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

As described below, the accounting policies applied are consistent with the policies applied in the financial statements for the accounts closed at the end of 2008.

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

The following standards, amendments and interpretations to published standards are mandatory for accounting periods beginning on or after 1 January 2009 but they are not relevant to the Group's operations:

- IAS 1 (Revised), 'Presentation of financial statements'
- IAS 36 (Amendment), 'Impairment of assets'
- IFRS 8, 'Operating segments'.

Standards, amendments and interpretations to existing standards that are not yet effective and have not been early adopted by the Group:

- IFRS 3 (Revised), 'Business combinations'
- IAS 19 (Amendment), 'Employee benefits'
- IAS 23 (Amendment), 'Borrowing costs'
- IAS 27 (Revised), 'Consolidated and separate financial statements'
- IAS 28 (Amendment), 'Investments in associates'
- IAS 31 (Amendment), 'Interest in joint ventures'
- IAS 32 (Amendment) 'Financial instruments: presentation'
- IAS 38 (Amendment), 'Intangible assets'
- IAS 39 (Amendment), 'Financial instruments: recognition and measurement'
- IFRS 2 (Amendment), 'Share based payment'
- IFRS 5 (Amendment) 'Non current assets held for sale and discontinued operations'
- IFRIC 16, 'Hedges of a net investment in a foreign operation'.

The additional disclosures required will be presented for the first time in the 2009 annual financial statements as they are not material for an understanding of the current interim period.

2. Segment information

Geographical segments

Although the Group's business is managed on a worldwide basis, it operates in seven main geographical areas. These are Benelux, France, Germany, North America, Scandinavia, British Isles (United Kingdom + Republic of Ireland) and Other Rest of the World countries.

€ Thousand Revenues	Q1/ 2009	Q1/ 2008
Benelux	19,637	16,714
France	28,896	26,054
Germany	31,883	32,735
North America	16,945	15,158
Scandinavia	30,297	30,445
British Isles	8,380	10,267
Other	12,204	8,213
Total	148,242	139,586

Revenues are based on the production country. For confidentiality reasons, the operating income by geographical areas is not provided.

3. Change in the scope 2009

Company	Country	Status	% of control	% of ownership	Consolidation method	Date of entry
		<i>Subsidiary of :</i>				
Chemlab AS	Norway	Eurofins Norge AS	100	100	Full consolidation	01/09

4. Balance sheet impact of the change of scope

During the first three months of 2009 the Company acquired new companies and carried out outsourcing/ asset deals. The fair values of assets and liabilities are as follows:

€ Thousand	Q1/ 2009
Fixed assets	-1,729
Goodwill and intangible assets related to an acquisition	750
Investments	0
Financial assets	4
Current assets excluding Cash	307
Corporate tax receivable	61
Cash	-306
Current liabilities	-1,285
Corporate taxes due	-194
Borrowings	1,708
Account payable on investment	-5,792
Deferred taxes	-60
Pension accrual	0
Provisions for risks	-133
Gain on end consolidation of subsidiaries	300
Minority interest	207
Total purchase price paid to date	-6,162
Less cash	306
Cash outflow on change of scope	-5,856

5. Contingencies

The contingencies are described in more detail in the Annual Report 2008 in the Note 4.2.

The liabilities/ borrowings listed below are already included in the Group's balance sheet. The following table only repeats these amounts when these borrowings are secured by covenants or securities on assets.

€ Thousand	31.03.2009	31.12.2008
Bank borrowings secured over buildings and assets	20,781	21,998
Leases secured over buildings and assets *	6,360	7,217
Bank borrowings secured by covenants and financial assets	0	0
Bank borrowings & OBSAR secured by covenants	235,715	254,018
Total	262,856	283,233

* Lease liabilities are effectively secured as the rights to the leased asset revert to the lessor in the event of default.

As March 31st 2009 the cash and cash equivalents are € 104,151k.

Detail of specific contingencies linked to acquisitions:

Rights to acquire or sell additional shares of a company have been signed at a formula price already fixed to be exercised during the period 2010-2015. The contingencies linked to the right to acquire or sell shares in this company (not yet booked in the consolidated balance sheet) are estimated at an amount of € 0.16m.

6. Changes in Equity

Share capital: At March 31st 2009, the total number of ordinary shares is 14.167 million shares with a par value of € 0.10 per share. All issued shares are fully paid.

During the first three months of 2009, the share capital increased by 5,450 new shares by exercise of employee stock options.

As at 31st March 2009, the Company did not own any of its own shares (number of own shares at December 31, 2008: 0).

Financial instruments:

To hedge the Group's exposure to interest rates fluctuations related to the OBSAR bonds, the Group has swapped its variable interest rate against a fixed rate.

Principal amount hedged with a fixed rate: € 100m.

The fair value 31st March 2009 of the financial instruments is estimated at an expense of € 5,240k.

Hybrid Bonds:

The structure of the hybrid bond ensures that it is recognized as a component of equity in accordance with IAS 32. For this reason, the tax-deductible interest payments are not included in interest expense, but accounted for in the same way as dividend obligations to shareholders. The interest expense accounted for during the first three months amounts to € 2,020k.

7. Stock option plans

Stock options are granted to directors and employees. Movements in the number of share options outstanding are as follows (amounts in thousands):

At beginning of the year	772
Options granted	114
Options exercised	-5
Options expired	0
At end of the period	881

8. Cash and Cash equivalents

€ Thousand	31.03.2009
Cash and cash equivalents - Balance Sheet	104,151
Operational overdrafts	-8,911
Cash and cash equivalents at end of period - Cash flow	95,240

9. Post closing events

N/A.

**STATUTORY AUDITORS' REVIEW REPORT ON THE FINANCIAL INFORMATION FROM
JANUARY 1st TO MARCH 31st, 2009**

To the Shareholders,

EUROFINS SCIENTIFIC SE
Rue Pierre Adolphe Bobierre
Boîte postale 42301
44323 NANTES CEDEX 3

This is a free translation into English of the Statutory Auditors' review report issued in French and is provided solely for the convenience of English speaking readers. This report should be read in conjunction with, and construed in accordance with, French law and professional auditing standards applicable in France.

At your request and as statutory auditor of your company, we hereby report to you on the accompanying condensed interim consolidated financial statements of Eurofins Scientific SE Company for the period January 1st to March 31st, 2009.

These condensed interim consolidated financial statements are the responsibility of the Company's management. Our role is to express a conclusion on these financial statements based on our review.

We conducted our review in accordance with professional standards applicable in France. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 - the standard of IFRSs as adopted by the European Union applicable to financial information.

Nantes May 13, 2009

The Statutory Auditors

PricewaterhouseCoopers Audit

HLP Audit

Benoit PINOCHE

Jacques HERON